The new SARCLISA J-code J9227 is now available, effective October 1, 2020, to be used for reimbursement claims. Refer to the Billing and Coding Guide on the Resources page for additional details. MAT-US-2018558-v1.0-08/2020

MECHANISM OF ACTION

SARCLISA Is a Multimodal Anti-CD38 mAb

Targeted binding to a specific epitope
induces distinct antitumor activity1-3

Back to topTop CareASSIST Patient Support